PL3773715T3 - Mirikizumab w leczeniu wrzodziejącego zapalenia jelita grubego - Google Patents

Mirikizumab w leczeniu wrzodziejącego zapalenia jelita grubego

Info

Publication number
PL3773715T3
PL3773715T3 PL19722256.5T PL19722256T PL3773715T3 PL 3773715 T3 PL3773715 T3 PL 3773715T3 PL 19722256 T PL19722256 T PL 19722256T PL 3773715 T3 PL3773715 T3 PL 3773715T3
Authority
PL
Poland
Prior art keywords
mirikizumab
treatment
ulcerative colitis
ulcerative
colitis
Prior art date
Application number
PL19722256.5T
Other languages
English (en)
Inventor
James Benedict CANAVAN
Stuart William FRIEDRICH
Kathryn Ann KRUEGER
Catherine MILCH
Jay Lawrence TUTTLE
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3773715T3 publication Critical patent/PL3773715T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL19722256.5T 2018-03-30 2019-03-28 Mirikizumab w leczeniu wrzodziejącego zapalenia jelita grubego PL3773715T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (en) 2018-03-30 2019-03-28 Methods of treating ulcerative colitis

Publications (1)

Publication Number Publication Date
PL3773715T3 true PL3773715T3 (pl) 2024-08-19

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19722256.5T PL3773715T3 (pl) 2018-03-30 2019-03-28 Mirikizumab w leczeniu wrzodziejącego zapalenia jelita grubego

Country Status (29)

Country Link
US (2) US12152072B2 (pl)
EP (2) EP3773715B1 (pl)
JP (4) JP7119114B2 (pl)
KR (1) KR102552693B1 (pl)
CN (1) CN111936165A (pl)
AU (2) AU2019243283C1 (pl)
BR (1) BR112020018099A2 (pl)
CA (1) CA3095297A1 (pl)
DK (1) DK3773715T3 (pl)
EA (1) EA202091989A1 (pl)
ES (1) ES2983809T3 (pl)
FI (1) FI3773715T3 (pl)
HR (1) HRP20240904T1 (pl)
HU (1) HUE067445T2 (pl)
IL (2) IL277514B2 (pl)
LT (1) LT3773715T (pl)
MA (1) MA52216B1 (pl)
MD (1) MD3773715T2 (pl)
MX (1) MX2020010269A (pl)
MY (1) MY202368A (pl)
PL (1) PL3773715T3 (pl)
PT (1) PT3773715T (pl)
RS (1) RS65661B1 (pl)
SG (1) SG11202009526RA (pl)
SI (1) SI3773715T1 (pl)
TW (2) TWI837532B (pl)
UA (1) UA128578C2 (pl)
WO (1) WO2019191464A1 (pl)
ZA (1) ZA202005388B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
EP4103606A4 (en) * 2020-02-14 2024-04-10 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD FOR TREATING ULCERATIVE COLITIS WITH ANTI-IL-12/IL23 ANTIBODIES
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
CA3207179A1 (en) * 2021-01-06 2022-07-14 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AU2022276189A1 (en) * 2021-05-20 2024-01-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2024521748A (ja) * 2021-05-28 2024-06-04 イーライ リリー アンド カンパニー 潰瘍性大腸炎に関与する遺伝子の抗il-23p19抗体調節
CN120569403A (zh) * 2022-11-22 2025-08-29 詹森生物科技公司 用抗il23特异性抗体治疗溃疡性结肠炎的方法
JP2025537966A (ja) 2023-03-10 2025-11-20 イーライ リリー アンド カンパニー 潰瘍性大腸炎を治療する方法
WO2024255867A1 (zh) * 2023-06-16 2024-12-19 信达生物制药(苏州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1896073E (pt) * 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
PT2548577T (pt) 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
SI2426144T1 (sl) 2007-02-23 2019-02-28 Merck Sharp & Dohme Corp. Umetno proizvedena anti-IL23P19 antitelesa
CA2741566A1 (en) * 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
JP7516250B2 (ja) * 2018-03-05 2024-07-16 ヤンセン バイオテツク,インコーポレーテツド 抗il-23特異的抗体を用いたクローン病の治療方法

Also Published As

Publication number Publication date
MA52216B1 (fr) 2024-07-31
PT3773715T (pt) 2024-05-27
TW202206104A (zh) 2022-02-16
TWI744617B (zh) 2021-11-01
US20250034243A1 (en) 2025-01-30
US12152072B2 (en) 2024-11-26
JP2023166388A (ja) 2023-11-21
BR112020018099A2 (pt) 2020-12-22
MX2020010269A (es) 2020-11-06
TWI837532B (zh) 2024-04-01
EP4327866B1 (en) 2025-12-10
SG11202009526RA (en) 2020-10-29
JP2021517156A (ja) 2021-07-15
NZ767902A (en) 2024-05-31
EA202091989A1 (ru) 2021-01-13
JP7571225B2 (ja) 2024-10-22
WO2019191464A1 (en) 2019-10-03
AU2019243283C1 (en) 2024-05-02
IL312807A (en) 2024-07-01
SI3773715T1 (sl) 2024-06-28
LT3773715T (lt) 2024-06-25
ZA202005388B (en) 2025-05-28
IL312807B1 (en) 2025-02-01
IL277514B1 (en) 2024-07-01
MY202368A (en) 2024-04-24
EP3773715B1 (en) 2024-05-08
MD3773715T2 (ro) 2024-10-31
TW201946657A (zh) 2019-12-16
CN111936165A (zh) 2020-11-13
EP4327866A3 (en) 2024-03-20
IL277514B2 (en) 2024-11-01
CA3095297A1 (en) 2019-10-03
HRP20240904T1 (hr) 2024-10-11
JP2025020134A (ja) 2025-02-12
AU2023248103A1 (en) 2023-11-09
EP4327866A2 (en) 2024-02-28
RS65661B1 (sr) 2024-07-31
EP3773715A1 (en) 2021-02-17
AU2019243283B2 (en) 2023-07-27
JP7331219B2 (ja) 2023-08-22
FI3773715T3 (fi) 2024-05-30
MA52216A (fr) 2021-02-17
US20210032325A1 (en) 2021-02-04
HUE067445T2 (hu) 2024-10-28
JP7119114B2 (ja) 2022-08-16
IL312807B2 (en) 2025-06-01
DK3773715T3 (da) 2024-05-27
UA128578C2 (uk) 2024-08-21
KR102552693B1 (ko) 2023-07-07
AU2019243283A1 (en) 2020-09-24
ES2983809T3 (es) 2024-10-24
IL277514A (en) 2020-11-30
KR20200128101A (ko) 2020-11-11
JP2022169562A (ja) 2022-11-09

Similar Documents

Publication Publication Date Title
HUS2500039I1 (hu) Elafibranor primer biliáris cirrózis kezelésében történõ alkalmazásra
PL3773715T3 (pl) Mirikizumab w leczeniu wrzodziejącego zapalenia jelita grubego
MA45192A (fr) Traitement d'association
DK3562486T3 (da) Anvendelse af sublingual dexmedetomidin til behandling af agitation
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
PL3265053T3 (pl) Sposoby leczenia skóry
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
EP3564335A4 (en) SURFACE TREATMENT AGENT
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
EP3409744A4 (en) SURFACE TREATMENT AGENT
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
EP3858943A4 (en) Surface treatment agent
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
DK3576738T3 (da) Gaboxadolmonohydrat i behandling af tinnitus
EP3431566A4 (en) SURFACE TREATMENT AGENT
EP3619170A4 (en) WATER TREATMENT PROCESS
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
DK3706739T3 (da) Anvendelse af riluzolprodrugs til behandling af ataksier
PL3331610T3 (pl) Środki do zastosowania w leczeniu glejaka
EP3493821A4 (en) METHOD OF TREATING THE RESPIRATORY TRACT
DK3243970T3 (da) Bruseafløb og gulv
HUE056798T2 (hu) Imatinib stroke kezelésében való alkalmazásra
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii